Key Highlights
- Tiffany Salas-Morris appointed as Chief Commercial Officer (CCO)
- Over two decades of expertise in life sciences and biotech
- Will drive commercial strategy to expand market presence and customer engagement
- Focus on scaling cell mimic technology to support advanced therapies
Source: Business Wire
Notable Quote
- “Mammotome is dedicated to providing innovative solutions that improve the biopsy experience for both patients and physicians. The Mammotome AutoCore™ system is the first core needle device of its kind, bringing in a new era of efficiency for ultrasound core needle breast biopsies. The launch of this device is a testament to our ongoing dedication to innovation and excellence in breast care.” — Karen Isaacs, Vice President of Engineering and R&D at Mammotome
SoHC's Take
Mammotome’s introduction of the AutoCore™ Single Insertion Core Biopsy System marks a substantial advancement in breast biopsy technology, setting a new standard for efficiency and precision. Its unique one-button functionality and automated tissue handling streamline biopsies, benefiting both clinicians and patients by saving valuable time and improving overall accuracy. This innovative approach positions Mammotome as a leader in patient-centered medical technology and underscores its commitment to enhancing clinical workflows and patient care. The FDA clearance ensures trusted quality for U.S. clinicians, and upcoming global availability promises to extend these benefits to a broader audience worldwide.
